m6A-centered Crosstalk Information

Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation
Crosstalk ID
M6ACROT05432
 [1]
m6A modification hsa-miR-25-3p hsa-miR-25-3p METTL3 Methylation : m6A sites Direct Enhancement Non-coding RNA miR-25-3p PTEN  lncRNA       miRNA   circRNA
m6A Modification:
m6A Regulator Methyltransferase-like 3 (METTL3) WRITER
 Regulator Info 
m6A Target hsa-miR-25-3p
 Targert Gene 
Epigenetic Regulation that have Cross-talk with This m6A Modification:
Epigenetic Regulation Type Non-coding RNA (ncRNA)
Epigenetic Regulator hsa-miR-25-3p microRNA View Details
Regulated Target Mutated in multiple advanced cancers 1 (PTEN) View Details
Crosstalk Relationship m6A  →  ncRNA Enhancement
Crosstalk Mechanism m6A regulators directly modulate the functionality of ncRNAs through specific targeting ncRNA
Crosstalk Summary METTL3 involves in the pathogenesis of diabetic retinopathy (DR). Both METTL3 mRNA and hsa-miR-25-3p were low-expressed in the peripheral venous blood samples of diabetes mellitus (DM) patients compared to normal volunteers, and high-glucose inhibited METTL3 and miR-25-3p expressions in RPE cells. Overexpression of METTL3 attenuates high-glucose induced RPE cell pyroptosis by regulating miR-25-3p/Mutated in multiple advanced cancers 1 (PTEN)/Akt signaling cascade through DGCR8.
Responsed Disease Diabetic retinopathy ICD-11: 9B71.0
 Disease Info 
Pathway Response PI3K-Akt signaling pathway hsa04151
Cell Process Cell viability
Cell apoptosis
Full List of Potential Compound(s) Related to This m6A-centered Crosstalk
9B71: Retinopathy 12 Compound(s) Regulating the Disease Click to Show/Hide the Full List
 Compound Name SHP607 Phase 2 [2]
External Link
TTD: D0R1JO
 Compound Name RST-001 Phase 1/2 [3]
Synonyms
ChR2 gene therapy (retinopathy), RetroSense; AAV-based ChR2 gene therapy (retinopathy), RetroSense; Channelrhodopsin-2 gene therapy (retinopathy), RetroSense
    Click to Show/Hide
External Link
TTD: D0RM6A
 Compound Name ReN-003 Phase 1/2 [4]
Synonyms
Stem cell therapy (retinal diseases), ReNeuron
    Click to Show/Hide
External Link
TTD: D03OVN
 Compound Name PMID28621580-Compound-WO2015089220C70 Patented [5]
External Link
TTD: D07AVU
 Compound Name SIR-1076 Preclinical [6]
Synonyms
Antioxidants (topical, retinal oxidative stress), Sirion Therapeutics
    Click to Show/Hide
External Link
TTD: D06RVY
 Compound Name CytoRet Investigative [4]
Synonyms
Retinal cell therapy (retinal disease), International Stem Cell; Retinal layers (parthenogenetic stem-cell derived), ISCO
    Click to Show/Hide
External Link
TTD: D0V4YT
 Compound Name LPO-1010CSR Investigative [4]
External Link
TTD: D0MH8K
 Compound Name INDUS-815C Investigative [7]
Synonyms
VEGF modulator (age related macular degeneration/retinopathy), Indus Biotech; INDUS-815C (Huntington's disease), Indus Biotech; INDUS-815C (age related macular degeneration/retinopathy), Indus Biotech; SIRT2 inhibtior (Parkinson's disease/dementia/Huntington's disease), Indus Biotech; NAD-dependent deacetylase sirtuin-2inhibitor (Parkinson's disease/dementia/Huntington's disease), Indus Biotech
    Click to Show/Hide
External Link
TTD: D0IR8J
 Compound Name SF-113 Investigative [4]
External Link
TTD: D0I2AD
 Compound Name SF-106 Investigative [4]
External Link
TTD: D07DRO
 Compound Name Gene therapy, retinopathy, Investigative [4]
Synonyms
Gene therapy (retinopathy)
    Click to Show/Hide
External Link
TTD: D04ENF
 Compound Name Superoxide dismutase mimetics Investigative [4]
Synonyms
INO-6001; INO-6002; Superoxide dismutase mimetics (retinal disease); Superoxide dismutase mimetics (retinal disease), Inotek; Superoxide dismutase mimetics (age-related macular degeneration/diabetic retinopathy/diabetic macular edema), Inotek
    Click to Show/Hide
External Link
TTD: D03KRF
References
Ref 1 Overexpression of METTL3 attenuates high-glucose induced RPE cell pyroptosis by regulating miR-25-3p/PTEN/Akt signaling cascade through DGCR8. Aging (Albany NY). 2020 May 4;12(9):8137-8150. doi: 10.18632/aging.103130. Epub 2020 May 4.
Ref 2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 3 ClinicalTrials.gov (NCT02556736) RST-001 Phase I/II Trial for Retinitis Pigmentosa.
Ref 4 The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
Ref 5 VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016). Expert Opin Ther Pat. 2017 Sep;27(9):987-1004. doi: 10.1080/13543776.2017.1344215. Epub 2017 Jun 23.
Ref 6 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800028168)
Ref 7 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2708).